Posted in | News | Nanomedicine | Nanomaterials

Spago Nanomedical Strengthens Tumorad® by Establishment of Scientific Advisory Board

Spago Nanomedical AB (publ) today announced the establishment of a Scientific Advisory Board (SAB) comprised of scientific and clinical leaders in oncology and nuclear medicine. The SAB will provide support and guidance in the clinical development of the radiopharmaceutical program Tumorad with the candidate drug 177Lu-SN201. At the outset the SAB consists of three prominent members; Professor Sten Nilsson, Professor Kristian Pietras and Dr. Austin Smith.

We are very pleased to assign Austin, Kristian and Sten to Spago Nanomedical’s Scientific Advisory Board for Tumorad. Together they provide a wealth of knowledge and experience in the development of novel radionucleotide therapies for cancer. Their collective expertise will be instrumental as we proceed Tumorad through the clinical and regulatory development phase, which recently commenced by the clinical trial application for a phase I/IIa study in patients with advanced cancer,” said CEO Mats Hansen.

The SAB will help guide the future direction of Tumorad’s clinical development. Reviewing ongoing data and contributing medical and scientific knowledge the Advisory Board will have an important role in ensuring the Tumorad program can meet its aims of bringing a new and valuable treatment option to the most appropriate patients. Additional members may be added to the Advisory Board as the program progresses.

The current members of the Tumorad SAB are:

Professor Sten Nilsson

Sten is a specialist and professor emeritus in oncology at the Department of Oncology-Pathology, Karolinska, as well as a specialist in nuclear medicine. Sten was responsible for the study design and led the early clinical program Xofigo (previously Alpharadin). Sten was previously the chairman of the Swedish Oncology Association (SOF) and the Swedish Association for Nuclear Medicine (SFNM) and member of EANM’s Radionuclide Therapy Task Force. He has published over 200 scientific articles.

Professor Kristian Pietras

Kristian is a professor in Molecular Medicine at Lund University, specializing in translational cancer research as a hub between basic science, clinical science and the pharmaceutical industry. Kristian has made important contributions in defining tumors as communicating organs comprising multiple cell types that collectively sustain cancer progression. Kristian has been a member and chairman of the Young Academy of Sweden, and is an elected member of the Royal Physiographic Society. He has published over 100 research articles and patents.

Dr. Austin Smith

Austin is trained and qualified in Medical Oncology and Pharmaceutical Medicine. Austin is a graduate of the Royal College of Surgeons, Ireland and has a solid background in all aspects of Oncology and Malignant Hematology, along with Regulatory Science experience across Europe, the US and Asia-Pacific regions, acting in senior and executive positions in biopharma companies. Austin is also a member of the Expert Group for Oncology, representing the Faculty of Pharmaceutical Medicine in the UK.

Source: https://spagonanomedical.se/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Spago Nanomedical AB. (2023, June 13). Spago Nanomedical Strengthens Tumorad® by Establishment of Scientific Advisory Board. AZoNano. Retrieved on February 24, 2024 from https://www.azonano.com/news.aspx?newsID=40279.

  • MLA

    Spago Nanomedical AB. "Spago Nanomedical Strengthens Tumorad® by Establishment of Scientific Advisory Board". AZoNano. 24 February 2024. <https://www.azonano.com/news.aspx?newsID=40279>.

  • Chicago

    Spago Nanomedical AB. "Spago Nanomedical Strengthens Tumorad® by Establishment of Scientific Advisory Board". AZoNano. https://www.azonano.com/news.aspx?newsID=40279. (accessed February 24, 2024).

  • Harvard

    Spago Nanomedical AB. 2023. Spago Nanomedical Strengthens Tumorad® by Establishment of Scientific Advisory Board. AZoNano, viewed 24 February 2024, https://www.azonano.com/news.aspx?newsID=40279.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit
Azthena logo

AZoM.com powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Azthena logo with the word Azthena

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.